Q2 2025 Earnings Call Transcript August 5, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $6.02, expectations ...

Non-GAAP earnings per share for Q2 2025 beat estimates by 14.0%, rising to $6.02 (non-GAAP) and up 21% year over year (non-GAAP). Revenue increased 9% to $9.2 billion, exceeding analyst expectations ...

Amgen AMGN reported second-quarter 2025 adjusted earnings of $6.02 per share, which beat the Zacks Consensus Estimate of ...

For the second quarter, total revenues increased 9% to $9.2 billion in comparison to the second quarter of 2024. Product sales grew 9%, driven by 13% volume g ...

DelveInsight's analysis underscores that as research continues and awareness grows, the cardiotoxicity market is poised for remarkable expansion and therapeutic innovation through 2032, supported by ...

Ligand to invest $35 million in exchange for a tiered royalty on future sales of Orchestra's AVIM therapy and Virtue SAB and an additional $5 million in an equity private placement • Medtronic to inve ...

Second quarter 2025 revenues increased 4% to $3.68 billion versus second quarter 2024Dupixent® global net sales (recorded by Sanofi) increased 22% to $4.34 billion EYLEA HD® U.S. net sales increased ...

In April 2025, the Trump administration introduced a major shift in trade policy by initially imposing a 37% tariff on Bangladeshi exports to the United States. This rate was later reduced to 35% and ...

Portfolio Receipts was $727 million in the second quarter of 2025, an increase of 20% compared to $608 million in the second quarter of 2024, primarily driven by the same Royalty Receipts increases ...

Amgen (NASDAQ:AMGN) surpasses Q2 earnings and revenue expectations with a 9.4% revenue growth. Read more here.

Fifteen of the biotechnology company’s products delivered at least double-digit sales growth in the second quarter including Repatha, Evenity and Imdelltra.

Amgen on Tuesday posted quarterly financial results that beat Wall Street expectations as a 9% increase in product sales ...